Hanmi Pharm (A128940) Stock Overview
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A128940 from our risk checks.
A128940 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hanmi Pharm. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩454,000.00 |
| 52 Week High | ₩647,000.00 |
| 52 Week Low | ₩267,500.00 |
| Beta | 0.43 |
| 1 Month Change | -8.19% |
| 3 Month Change | -25.57% |
| 1 Year Change | 55.48% |
| 3 Year Change | 56.45% |
| 5 Year Change | 36.68% |
| Change since IPO | 627.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| A128940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.9% | -0.9% | 4.6% |
| 1Y | 55.5% | 27.3% | 186.7% |
Return vs Industry: A128940 exceeded the KR Pharmaceuticals industry which returned 21% over the past year.
Return vs Market: A128940 underperformed the KR Market which returned 184.3% over the past year.
Price Volatility
| A128940 volatility | |
|---|---|
| A128940 Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A128940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A128940's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 2,330 | Jae-Hyun Park | www.hanmipharm.com |
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED).
Hanmi Pharm. Co., Ltd. Fundamentals Summary
| A128940 fundamental statistics | |
|---|---|
| Market cap | ₩5.76t |
| Earnings (TTM) | ₩169.55b |
| Revenue (TTM) | ₩1.55t |
Is A128940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A128940 income statement (TTM) | |
|---|---|
| Revenue | ₩1.55t |
| Cost of Revenue | ₩663.12b |
| Gross Profit | ₩884.41b |
| Other Expenses | ₩714.85b |
| Earnings | ₩169.55b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.37k |
| Gross Margin | 57.15% |
| Net Profit Margin | 10.96% |
| Debt/Equity Ratio | 29.9% |
How did A128940 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 10:14 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hanmi Pharm. Co., Ltd. is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyonseok Kim | CLSA |
| Heeyoung Lee | Daishin Securities Co. Ltd. |
| Ka-hye Hong | Daishin Securities Co. Ltd. |